Optional intermediate doses The chart above includes several "optional intermediate" doses at 0.75mg, 1.25mg, 1.5mg, and 2.0mg
These drugs, known as glucagon-like peptide-1 receptor agonists or GLP-1 medications, have gained attention for their role in helping people manage type 2 diabetes, and more recently, for their weight loss benefits
The FDA updated Ozempics label in September 2023 to warn about intestinal blockages as a potential side effect of the drug
You should only use a clean unused needle with the correct measurements on it for what you are prescribed to use
Particular focus was on IcoSema, a new drug by Novo Nordisk that combines once-weekly insulin icodec (approved in Europe and other countries, but not yet the U.S.) and semaglutide, a GLP-1 agonist